Sun Pharma inks two deals with China Medical System

Indian pharma major Sun Pharmaceutical Industries (BSE: 524715) has entered into a licensing agreement with a subsidiary of China Medical System Holdings (CMS) for the development and commercialization of tildrakizumab, an innovative biologic product, for psoriasis and psoriatic arthritis, in Greater China (including Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region and Taiwan).

Under terms of the license agreement, CMS will make an initial upfront payment, regulatory and sales milestone payments, and royalties on net sales to Sun Pharma, the terms of which are confidential. CMS will be responsible for development, regulatory filings and commercialization of the product in China. The initial tenure of the agreement shall be 15 years from the first commercial sale of tildrakizumab in Greater China, and may be extended for an additional three years, subject to certain conditions defined in the agreement.

“This licensing agreement marks our entry into the Greater China market which is the second largest pharmaceutical market globally. Sun Pharma is committed to growing its dermatology franchise, with tildrakizumab as its lead product. We continue to build our pipeline and capabilities in this important therapeutic area of significant unmet need. We are excited to be partnering with a leading pharmaceutical company like CMS to offer tildrakizumab as an alternative treatment for psoriasis and psoriatic arthritis in Greater China,” said Dilip Shanghvi, managing director, Sun Pharma.